|Presenter:||Professor Jeffrey Gorman, QIMR|
|Title:||Proteomic dissection of the battle between respiratory syncytial virus and epithelial cells during infection|
|Date:||28 March 2013|
|Venue:||Parnell Building 07, Lecture Room 222|
Professor Jeff Gorman is the Leader of the Protein Discovery Group at QIMR and National Convenor of Proteomics Australia. He’s spent more than 40 years working in biomedical research, holding positions at Institutes in Melbourne, Sydney and at the US NIH. He moved to Queensland in 2003 to take up a joint appointment involving CSIRO and UQ/IMB. Professor Gorman relocated in 2006 to establish proteomic capabilities at QIMR.
His career has involved just about all aspects of protein chemistry from isolation of naturally occurring peptides and proteins through to peptide and nucleic acid synthesis. He was the first Australian scientist to procure a mass spectrometer solely for the purpose of protein analysis, now called proteomics.
Respiratory syncytial virus (RSV) is a serious respiratory pathogen, especially in the early and late stages of life. RSV is a member of the paramyxoviridae family of viruses and has the characteristic of not initiating a sustainable immune response. There are no vaccines licensed to prevent RSV or efficacious therapeutic agents for RSV. Prof Gorman’s group is aiming to gain a better understanding of how RSV negates host cell antiviral responses with the aim of identification of antiviral targets for treatment of RSV infections.
RSV utilises specific non-structural (NS) proteins to dampen host cell responses, particularly interferon induction and signalling, by interactions with host cell proteins. Despite the obvious importance of the interactions between RSVNS and host cell proteins, the targets of the NS proteins and their mechanisms of action have not been adequately defined. Accordingly we have been using advanced proteomic technologies to establish the baseline of changes that occur upon infection of epithelial cells with RSV and the impacts of the NS protein on these changes. This presentation will describe the strategies in use and findings showing that RSV NS1 abrogates type II interferon responses as well as non-interferon regulated apoptotic responses.